Petitou M, Duchaussoy P, Jaurand G, Gourvenec F, Lederman I, Strassel J M, Bârzu T, Crépon B, Hérault J P, Lormeau J C, Bernat A, Herbert J M
Haemobiology Research Department, Sanofi Recherche, Toulouse, France.
J Med Chem. 1997 May 23;40(11):1600-7. doi: 10.1021/jm960726z.
The synthetic pentasaccharide (1) corresponding to the heparin sequence which binds to, and activates, antithrombin III (AT III) is a potent antithrombotic compound in several animal models of venous thrombosis. We describe here the preparation and the pharmacological properties of 34, an analogue of oligosaccharide 1 with the latter's N-sulfates being replaced by sulfate esters and hydroxyl groups being methylated. These structural modifications allow a simpler and more efficient synthesis of such anionic oligosaccharides. Affinity for human AT III, anti-factor Xa activity, ability to inhibit thrombin generation, antithrombotic activity in a rat model of venous thrombosis, and elimination half-life in the rat have been determined for 1 and 34. Surprisingly, introduction of O-sulfates in place of N-sulfates, and methylation of hydroxyl groups, contributes to reinforce the binding to AT III, resulting in an improved pharmacological profile.
与抗凝血酶III(AT III)结合并激活的肝素序列对应的合成五糖(1)在几种静脉血栓形成的动物模型中是一种有效的抗血栓化合物。我们在此描述34的制备及其药理学特性,34是寡糖1的类似物,其中寡糖1的N-硫酸盐被硫酸酯取代,羟基被甲基化。这些结构修饰使得此类阴离子寡糖的合成更简单、更高效。已测定了1和34对人AT III的亲和力、抗Xa因子活性、抑制凝血酶生成的能力、在大鼠静脉血栓形成模型中的抗血栓活性以及在大鼠体内的消除半衰期。令人惊讶的是,用O-硫酸盐取代N-硫酸盐以及羟基的甲基化有助于增强与AT III的结合,从而改善药理学特性。